{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:06:37Z","timestamp":1773090397621,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41585-018-0083-0","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T04:18:47Z","timestamp":1535602727000},"page":"721-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunotherapy for advanced penile cancer \u2014 rationale and potential"],"prefix":"10.1038","volume":"15","author":[{"given":"Bradley","family":"McGregor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"key":"83_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00345-008-0302-z","volume":"27","author":"MC Bleeker","year":"2009","unstructured":"Bleeker, M. C. et al. Penile cancer: epidemiology, pathogenesis and prevention. World J. Urol. 27, 141\u2013150 (2009).","journal-title":"World J. Urol."},{"key":"83_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fphar.2016.00487","volume":"7","author":"C Buonerba","year":"2016","unstructured":"Buonerba, C. et al. Prognostic and predictive factors in patients with advanced penile cancer receiving salvage (2nd or later line) systemic treatment: a retrospective, multi-center study. Front. Pharmacol. 7, 487 (2016).","journal-title":"Front. Pharmacol."},{"key":"83_CR3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jcp.2008.063149","volume":"62","author":"C Miralles-Guri","year":"2009","unstructured":"Miralles-Guri, C. et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J. Clin. Pathol. 62, 870\u2013878 (2009).","journal-title":"J. Clin. Pathol."},{"key":"83_CR4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovic","year":"2015","unstructured":"Stevanovic, S. et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 33, 1543\u20131550 (2015).","journal-title":"J. Clin. Oncol."},{"key":"83_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386, 2078\u20132088 (2015).","journal-title":"Lancet"},{"key":"83_CR6","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"83_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"83_CR8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CJI.0000000000000221","volume":"41","author":"DT Trafalis","year":"2018","unstructured":"Trafalis, D. T. et al. Evidence for efficacy of treatment with the anti-PD-1 Mab nivolumab in radiation and multichemorefractory advanced penile squamous cell carcinoma. J. Immunother. 41, 300\u2013305 (2018).","journal-title":"J. Immunother."},{"key":"83_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","volume":"197","author":"SR Ottenhof","year":"2017","unstructured":"Ottenhof, S. R. et al. Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status. J. Urol. 197, 690\u2013697 (2017).","journal-title":"J. Urol."},{"key":"83_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bju.14013","volume":"121","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int. 121, 348\u2013356 (2018).","journal-title":"BJU Int."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0083-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0083-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0083-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:24:18Z","timestamp":1684607058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-018-0083-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1038\/s41585-018-0083-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735550881.793558985","asserted-by":"object"}]},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"assertion":[{"value":"30 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.M. is a consultant for Bayer, Astellas, AstraZeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, and Genentech; and has received research support (institutional) from Bristol Myers Squibb (BMS) and speaker fees from Clinical Care Options and OncLive. G.S. is a consultant for Bayer, Sanofi, Pfizer, Novartis, Eisai, Janssen, Amgen, AstraZeneca, Merck, Genentech, Argos, EMD Serono and Agensys\/Astellas; has received research support (institutional) from Bayer, Onyx, Celgene, Boehringer-Ingelheim, Merck, Pfizer, Sanofi, Janssen, AstraZeneca, and BMS; has received speaker fees from Clinical Care Options, Physicians Education Resource (PER), Research to Practice (RTP), and Onclive; and is an author for Uptodate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}